These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

426 related articles for article (PubMed ID: 33219624)

  • 21. Impact of menopausal status on background parenchymal enhancement and fibroglandular tissue on breast MRI.
    King V; Gu Y; Kaplan JB; Brooks JD; Pike MC; Morris EA
    Eur Radiol; 2012 Dec; 22(12):2641-7. PubMed ID: 22752463
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Automated fibroglandular tissue segmentation and volumetric density estimation in breast MRI using an atlas-aided fuzzy C-means method.
    Wu S; Weinstein SP; Conant EF; Kontos D
    Med Phys; 2013 Dec; 40(12):122302. PubMed ID: 24320533
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MRI Background Parenchymal Enhancement Is Not Associated with Breast Cancer.
    Bennani-Baiti B; Dietzel M; Baltzer PA
    PLoS One; 2016; 11(7):e0158573. PubMed ID: 27379395
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Computerized assessment of background parenchymal enhancement on breast dynamic contrast-enhanced-MRI including electronic lesion removal.
    Douglas L; Fuhrman J; Hu Q; Edwards A; Sheth D; Abe H; Giger M
    J Med Imaging (Bellingham); 2024 May; 11(3):034501. PubMed ID: 38737493
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The impact of bilateral salpingo-oophorectomy on breast MRI background parenchymal enhancement and fibroglandular tissue.
    Price ER; Brooks JD; Watson EJ; Brennan SB; Comen EA; Morris EA
    Eur Radiol; 2014 Jan; 24(1):162-8. PubMed ID: 23982290
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Histopathologic characteristics of background parenchymal enhancement (BPE) on breast MRI.
    Sung JS; Corben AD; Brooks JD; Edelweiss M; Keating DM; Lin C; Morris EA; Patel P; Robson M; Woods M; Bernstein JL; Pike MC
    Breast Cancer Res Treat; 2018 Nov; 172(2):487-496. PubMed ID: 30140962
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Post-Processing Bias Field Inhomogeneity Correction for Assessing Background Parenchymal Enhancement on Breast MRI as a Quantitative Marker of Treatment Response.
    Nguyen AA; Onishi N; Carmona-Bozo J; Li W; Kornak J; Newitt DC; Hylton NM
    Tomography; 2022 Mar; 8(2):891-904. PubMed ID: 35448706
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intraindividual Comparison of Different Methods for Automated BPE Assessment at Breast MRI: A Call for Standardization.
    Müller-Franzes G; Khader F; Tayebi Arasteh S; Huck L; Bode M; Han T; Lemainque T; Kather JN; Nebelung S; Kuhl C; Truhn D
    Radiology; 2024 Jul; 312(1):e232304. PubMed ID: 39012249
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of Breast Cancer Odds with Background Parenchymal Enhancement Quantified Using a Fully Automated Method at MRI: The IMAGINE Study.
    Watt GP; Thakran S; Sung JS; Jochelson MS; Lobbes MBI; Weinstein SP; Bradbury AR; Buys SS; Morris EA; Apte A; Patel P; Woods M; Liang X; Pike MC; Kontos D; Bernstein JL
    Radiology; 2023 Sep; 308(3):e230367. PubMed ID: 37750771
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Automated rating of background parenchymal enhancement in MRI of extremely dense breasts without compromising the association with breast cancer in the DENSE trial.
    Wang H; H M van der Velden B; Verburg E; Bakker MF; Pijnappel RM; Veldhuis WB; van Gils CH; Gilhuijs KGA
    Eur J Radiol; 2024 Jun; 175():111442. PubMed ID: 38583349
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multiparametric
    Leithner D; Helbich TH; Bernard-Davila B; Marino MA; Avendano D; Martinez DF; Jochelson MS; Kapetas P; Baltzer PAT; Haug A; Hacker M; Tanyildizi Y; Morris EA; Pinker K
    J Nucl Med; 2020 Jan; 61(1):20-25. PubMed ID: 31253745
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quantitative Measures of Background Parenchymal Enhancement Predict Breast Cancer Risk.
    Niell BL; Abdalah M; Stringfield O; Raghunand N; Ataya D; Gillies R; Balagurunathan Y
    AJR Am J Roentgenol; 2021 Jul; 217(1):64-75. PubMed ID: 32876474
    [No Abstract]   [Full Text] [Related]  

  • 33. Preliminary analysis: Background parenchymal 18F-FDG uptake in breast cancer patients appears to correlate with background parenchymal enhancement and to vary by distance from the index cancer.
    Kim E; Mema E; Axelrod D; Sigmund E; Kim SG; Babb J; Melsaether AN
    Eur J Radiol; 2019 Jan; 110():163-168. PubMed ID: 30599855
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of Prostate MRI Lesion Segmentation Agreement Between Multiple Radiologists and a Fully Automatic Deep Learning System.
    Schelb P; Tavakoli AA; Tubtawee T; Hielscher T; Radtke JP; Görtz M; Schütz V; Kuder TA; Schimmöller L; Stenzinger A; Hohenfellner M; Schlemmer HP; Bonekamp D
    Rofo; 2021 May; 193(5):559-573. PubMed ID: 33212541
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of aromatase inhibitors on background parenchymal enhancement and amount of fibroglandular tissue at breast MR imaging.
    King V; Goldfarb SB; Brooks JD; Sung JS; Nulsen BF; Jozefara JE; Pike MC; Dickler MN; Morris EA
    Radiology; 2012 Sep; 264(3):670-8. PubMed ID: 22771878
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Background parenchymal enhancement and fibroglandular tissue on breast MRI in women with high genetic risk: Are changes before and after risk-reducing salpingo-oophorectomy associated with breast cancer risk?
    Bermot C; Saint-Martin C; Malhaire C; Sebbag-Sfez D; Mouret-Fourme E; Carton M; Thibault FE
    Eur J Radiol; 2018 Dec; 109():171-177. PubMed ID: 30527300
    [TBL] [Abstract][Full Text] [Related]  

  • 37. IDH1 mutation prediction using MR-based radiomics in glioblastoma: comparison between manual and fully automated deep learning-based approach of tumor segmentation.
    Choi Y; Nam Y; Lee YS; Kim J; Ahn KJ; Jang J; Shin NY; Kim BS; Jeon SS
    Eur J Radiol; 2020 Jul; 128():109031. PubMed ID: 32417712
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quantitative assessment of background parenchymal enhancement is associated with lifetime breast cancer risk in screening MRI.
    Yan R; Murakami W; Mortazavi S; Yu T; Chu FI; Lee-Felker S; Sung K
    Eur Radiol; 2024 Oct; 34(10):6358-6368. PubMed ID: 38683385
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of tamoxifen on amount of fibroglandular tissue, background parenchymal enhancement, and cysts on breast magnetic resonance imaging.
    King V; Kaplan J; Pike MC; Liberman L; David Dershaw D; Lee CH; Brooks JD; Morris EA
    Breast J; 2012; 18(6):527-34. PubMed ID: 23002953
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mammographic density, MRI background parenchymal enhancement and breast cancer risk.
    Pike MC; Pearce CL
    Ann Oncol; 2013 Nov; 24 Suppl 8(Suppl 8):viii37-viii41. PubMed ID: 24131968
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.